India, April 4 -- Drug major Johnson & Johnson (JNJ) announced Friday positive results from the TREMFYA (guselkumab) Phase 3b APEX study in adults living with active psoriatic arthritis or PsA, compared to placebo.
The company noted that TREMFYA demonstrated clinically meaningful and statistically significant efficacy in patients with active PsA at risk for structural damage in Phase 3b study.
PsA is a chronic, immune-mediated, inflammatory disease characterized by peripheral joint inflammation, enthesitis, dactylitis, axial disease and the skin lesions associated with plaque psoriasis.
Johnson & Johnson's TREMFYA, a prescription medicine, is the first approved fully-human, dual-acting monoclonal antibody designed to neutralize inflammat...